Homeopathy as an add-on to standard treatment of pulmonary tuberculosis

Effectiveness of Individualized homeopathy as an add on to standard treatment of Pulmonary tuberculosis- a randomized parallel arm double blind, placebo-controlled study (HAPT Trial) - HAPT – trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/076062

Enrollment

296

Registered

2024-10-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A159- Respiratory tuberculosis unspecified

Interventions

Intervention1: Homoeopathic medicine along with standard care: Homoeopathic medicines will be given to this group patients as an add-on to standard treatmet. Following Individualization medicines will

Eligibility

Inclusion criteria

Inclusion criteria: Pulmonary tuberculosis patients with positive sputum culture. Patients with controlled Diabetes mellites and hypertension with medication. Patients who are willing to give written informed consent

Exclusion criteria

Exclusion criteria: Participation in another clinical trial. Female patients in lactation period, pregnancy or planning to get pregnant during the trial. Known patients with severe primary diseases such as cancer, cardiovascular system, digestive system, kidney, and hematopoietic system diseases. Patients co-infected with HIV. Patients with mental illness. Subjects considered to be unable to complete the study, or not suitable for the study by researchers.

Design outcomes

Primary

Measure	Time frame
Clinical recovery of patient, termed as cure as per WHO criteria (Cure).Timepoint: At 2nd, 3rd, 4th, 5th, 6th, 12th & 18th month	—

Secondary

Measure	Time frame
Time to resolution of all pulmonary tuberculosis symptoms. Timepoint: At 2nd, 3rd, 4th, 5th, 6th, 12th & 18th month;Change in severity of symptoms/resolution as per clinical syndromes associated with Pulmonary tuberculosis at every month.Timepoint: every month;Time to sputum conversion.Timepoint: At 2nd, 3rd, 4th, 5th, 6th, 12th & 18th month;Resolution of chest X-ray changes of lungsTimepoint: At 2nd, 6th, & 12th month;Change in Erythrocyte Sedimentation RateTimepoint: At 2nd, 6th, & 12th month.;Change in C-reactive protein.Timepoint: At 2nd, 6th, & 12th month;Relapse in patients after 1 year of completion of treatmentTimepoint: at 12 month;Adverse events throughout the study.Timepoint: every month;Compare Quality of Life (WHOQOL-Bref) in patients.Timepoint: at 2nd, 6th, 12th & 18th month	—

Measure

Time frame

Time to resolution of all pulmonary tuberculosis symptoms. Timepoint: At 2nd, 3rd, 4th, 5th, 6th, 12th & 18th month;Change in severity of symptoms/resolution as per clinical syndromes associated with Pulmonary tuberculosis at every month.Timepoint: every month;Time to sputum conversion.Timepoint: At 2nd, 3rd, 4th, 5th, 6th, 12th & 18th month;Resolution of chest X-ray changes of lungsTimepoint: At 2nd, 6th, & 12th month;Change in Erythrocyte Sedimentation RateTimepoint: At 2nd, 6th, & 12th month.;Change in C-reactive protein.Timepoint: At 2nd, 6th, & 12th month;Relapse in patients after 1 year of completion of treatmentTimepoint: at 12 month;Adverse events throughout the study.Timepoint: every month;Compare Quality of Life (WHOQOL-Bref) in patients.Timepoint: at 2nd, 6th, 12th & 18th month

—

Countries

India

Contacts

Public ContactDr. Saurabh

Autonomous State Medical College

sidaga21@gmail.com9359934663

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026